Celltrion Reports 2Q Sales of 431.8 Billion KRW and Operating Profit of 163.1 Billion KRW

Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Hyunmin Kim kimhyun81@

[Asia Economy Reporter Lee Chun-hee] Celltrion announced its second-quarter sales of 431.8 billion KRW and operating profit of 163.1 billion KRW.

Celltrion disclosed on the 13th that its consolidated (provisional) operating results for the second quarter were sales of 431.769 billion KRW, operating profit of 163.11 billion KRW, and net profit of 129.538 billion KRW. Compared to the same period last year, these figures represent increases of 0.69%, decreases of 10.25%, and decreases of 6.54%, respectively.

For the first half of the year combined, sales reached 888.7 billion KRW, a 17.5% growth compared to 756.6 billion KRW in the first half of last year, firmly securing membership in the '1 trillion KRW sales club' for the third consecutive year. Operating profit also increased by 22.8% to 370.9 billion KRW, and net profit rose by 34.0% to 326.8 billion KRW.

Celltrion stated, "The increase in second-quarter sales compared to the same period last year was driven by expanded sales of existing antibody biosimilar products such as Remsima and Truxima." Regarding the decrease in operating profit in the second quarter, they explained, "To respond to demand for Remsima in the U.S., ensure stable global supply of Regkirona, and secure inventory of Truxima, which has high market demand, strategic pre-production of these products was necessary, leading to a temporary decline in profitability due to adjustments in the factory production portfolio." They added, "The operating profit margin remains stable at around 37%."

A Celltrion official said, "Sales of Remsima and Truxima continue to increase as demand grows steadily in the U.S. market following Europe, and in the second half of the year, significant growth in sales and operating profit is expected through expanded supply of high value-added products such as Remsima SC and Regkirona." He added, "In addition to expanding the market for existing products, we will also do our best to secure technological capabilities for new growth engines such as ADC and messenger RNA (mRNA) vaccines."

This content was produced with the assistance of AI translation services.